---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-077410"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-07-03T23:59:59+00:00"
generated_at: "2026-06-13T13:29:01.750880+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma reports $24.5M cash, runway into H1 2025

## Summary
- Cash and equivalents of $24.5M at June 30, 2023, up ~$9.0M from March 31, 2023.
- Increase primarily from exercise of previously issued preferred investment options in Q2 2023.
- Company estimates current cash sufficient to fund planned operations into first half of 2025.
- Cash figure is preliminary, subject to change upon completion of period-end close.

## SEC filing metadata
- accession: 0001104659-23-077410
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/0001104659-23-077410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923077410/tm2320415d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-077410
- JSON: https://secwatch.observer/filing/0001104659-23-077410.json
- Plain text: https://secwatch.observer/filing/0001104659-23-077410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.